Marshall Health Network performs West Virginia’s first histotripsy at Cabell Huntington Hospital

Innovative noninvasive technology uses focused sound waves to destroy targeted liver tumors 

Marshall Health Network-Cabell Huntington Hospital (CHH) has successfully treated West Virginia’s first patient using histotripsy, a groundbreaking technology that uses focused sound waves to destroy targeted liver tumors without an incision.

The outpatient procedure was performed by Paul Blom, M.D., interventional radiologist with Radiology, Inc., using the Edison® Histotripsy System. The patient was able to return home just hours after the procedure.

“This is an important milestone for cancer care in West Virginia and, more importantly, for patients who may now have access to a completely noninvasive treatment option closer to home,” said Blom. “To be able to precisely target and destroy tumor tissue without an incision represents a significant advancement in the way we can approach certain liver tumors. We’re proud to bring this technology to our patients and our region.”

CHH is the first and only hospital in West Virginia to offer the Edison Histotripsy System, an FDA-cleared technology for the treatment of liver tumors. The acquisition was made possible through a $1.3 million gift from the Cabell Huntington Hospital Auxiliary, supporting the organization’s continued investment in advanced technology and patient care.

“Bringing histotripsy to West Virginia is another example of how we are expanding access to advanced care for patients in our region,” said Tim Martin, president of Cabell Huntington Hospital. “We are especially grateful to the Cabell Huntington Hospital Auxiliary. Their generosity made this investment possible and is directly helping us bring an important new treatment option to the patients we serve.” 

For more information about histotripsy at Cabell Huntington Hospital, visit cabellhuntington.org/histotripsy.  To learn more about the Edison System, visit: histosonics.com.